CN116087386A - Human insulin-like growth factor detection method and kit - Google Patents
Human insulin-like growth factor detection method and kit Download PDFInfo
- Publication number
- CN116087386A CN116087386A CN202310378354.9A CN202310378354A CN116087386A CN 116087386 A CN116087386 A CN 116087386A CN 202310378354 A CN202310378354 A CN 202310378354A CN 116087386 A CN116087386 A CN 116087386A
- Authority
- CN
- China
- Prior art keywords
- igf
- standard
- solution
- detection
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 68
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 29
- 102000013275 Somatomedins Human genes 0.000 title claims abstract description 14
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000012224 working solution Substances 0.000 claims abstract description 36
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 22
- 230000005593 dissociations Effects 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 238000003908 quality control method Methods 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims abstract description 15
- 239000012530 fluid Substances 0.000 claims abstract description 14
- 238000011068 loading method Methods 0.000 claims abstract description 11
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims abstract description 11
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 10
- 238000001819 mass spectrum Methods 0.000 claims abstract description 10
- 238000000746 purification Methods 0.000 claims abstract description 9
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims abstract 12
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims abstract 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- 239000000047 product Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000012086 standard solution Substances 0.000 claims description 11
- 230000006920 protein precipitation Effects 0.000 claims description 8
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 239000012488 sample solution Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000001948 isotopic labelling Methods 0.000 claims description 4
- 238000013207 serial dilution Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000004907 flux Effects 0.000 abstract description 4
- 230000001376 precipitating effect Effects 0.000 abstract description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 85
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 61
- 102000057877 human IGF2 Human genes 0.000 description 60
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 14
- 239000012472 biological sample Substances 0.000 description 14
- 102000057148 human IGFBP3 Human genes 0.000 description 14
- 206010056438 Growth hormone deficiency Diseases 0.000 description 12
- 108010051696 Growth Hormone Proteins 0.000 description 11
- 102100038803 Somatotropin Human genes 0.000 description 11
- 239000000122 growth hormone Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 238000002386 leaching Methods 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- AJEHNBIPLQJTNU-UHFFFAOYSA-N cyanomethyl acetate Chemical compound CC(=O)OCC#N AJEHNBIPLQJTNU-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 2
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000012716 precipitator Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100348341 Caenorhabditis elegans gas-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 229910005541 GaS2 Inorganic materials 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 101100447658 Mus musculus Gas1 gene Proteins 0.000 description 1
- 101100447665 Mus musculus Gas2 gene Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention mainly relates to a method and a kit for detecting human insulin-like growth factors, wherein the method comprises the following steps: dissociation of proteins; precipitating protein; and (3) solid phase extraction and purification: mass spectrometry detection: loading LC-MS/MS detection to obtain the Area Ratio value of the sample to be detected; and (3) calculating: and replacing the sample to be detected with the standard working solution, repeating the pretreatment step and the mass spectrum detection step to obtain a standard curve, substituting the Area Ratio value of the sample to be detected into the standard curve, and calculating the content of IGF-I and IGF-II. The kit comprises: a dissociating agent; a precipitant; standard working solution; a quality control product working solution; the standard internal standard fluid comprises an isotopically labeled diluent of IGF-I. The complexity of the pretreatment process is obviously reduced, IGF-I and IGF-II can be detected simultaneously, the method has high sensitivity, strong specificity, good accuracy, high precision, short detection time and high detection flux.
Description
Technical Field
The invention mainly relates to the technical field of medical detection, in particular to a method and a kit for detecting human insulin-like growth factors.
Background
Growth Hormone Deficiency (GHD) is a disease causing short stature of children, is mostly caused by insufficient secretion of Growth Hormone (GH) by pituitary gland, clinically manifests as symptoms of short stature, normal intelligence, slow bone growth and the like, and has bone age behind normal children of the same age, and can also cause changes of bone metabolism and sugar metabolism to seriously influence the growth of children.
GHD diagnosis has no gold standard at present, laboratory examination uses GH excitation test as main diagnosis basis, but GH is unstable, takes pulse and has circadian rhythm, and needs injection medicine excitation to have higher level score. GH excitation test requires 5 times of blood drawing within 2 hours, and has poor repeatability and accuracy and more influencing factors. Serum IGF-I (human insulin-like growth factor-I) is relatively stable without obvious pulse secretion and circadian rhythm, and can better reflect the endogenous GH secretion state, so that the serum IGF-I is once considered as a screening index of GHD. Clinical examination of primary patients with GHD or of individuals with height monitoring generally preceded IGF-I and IGFBP-3 (human insulin-like growth factor binding protein 3), combined with these two results and clinical manifestations, the GH detection was performed in the suspected case of GHD.
Human insulin-like growth factor (IGF) is a group of polypeptide substances with growth promoting effect, secretion cells of the IGF are widely distributed in tissues such as human liver, kidney, lung, heart and intestine, the IGF family comprises IGF-I and IGF-II (human insulin-like growth factor-II), IGF-I is an alkaline peptide containing 70 amino acids and coded by a gene of chromosome 12, has a structure similar to insulin, can mediate the growth promoting effect of GH on organisms, has strong growth promoting effect and is an important growth factor in childhood, and IGF-I synthesized in each tissue plays the growth promoting effect in a self-secretion or paracrine mode, so researches show that the change of IGF-I, IGFBP-3 level is closely related to GHD; insulin-like action of IGF-II is stronger, is a single-chain peptide containing 67 amino acids and plays an important role in fetal growth, and early papers indicate that IGF-I/IGF-II performance is superior to IGF-I single-test or IGF-I+IGFBP-3 dual-test performance in judging whether children suffer from GHD.
The detection method commonly used in IGF-I detection in the current market is a chemiluminescence method, wherein the detection of IGFBP-3 is mainly due to the fact that 95% of IGF-I in blood is combined with the IGFBP-3, and the influence of IGFBP-3 is still avoided even if the IGFBP-3 is treated before detection. Meanwhile, the detection limit of the current detection method is 25ng/mL, and the IGF-I content in the blood of the low-age children is generally below 10ng/mL, so the detection limit defect exists in the method. The mass spectrometry detection of IGF-I can avoid the influence of IGFBP-3, realize the accurate quantification of IGF-I, and is hopeful to omit IGFBP-3 detection; on the other hand, the detection limit can reach below 10ng/mL, thereby realizing the detection of low-concentration IGF-I. IGF-II is a loop in the GH-IGF axis and is theoretically possible to influence the GH-IGF axis and thus the GH secretion, and studies have shown that IGF-I/IGF-II performance is superior to IGF-I screening or IGF-I+IGFBP-3 performance in determining whether children are GHD. Therefore, the simultaneous quantitative detection of IGF-I and IGF-II can help to screen out GHD patients better clinically, thereby obtaining effective treatment.
In the prior art, there are few quantitative detection patents for IGF-I and/or IGF-II, and only the application number of the intelligent organism is 202210059159, the invention name is a quantitative detection kit and a detection method for insulin sample growth factor-I based on MALDI-TOF+MS, and the invention patent applications of the Nyquist diagnosis investment company with the grant publication numbers of CN105067698B and CN 102596230B. The invention of the intelligent organism is mainly based on detection and quantification of IGF-I by MALDI-TOF technology, and the quantification adopts a nonlinear fitting mode according to the characteristics of the mass spectrum; in addition, in the selection of lysate (dissociating agent), protein denaturant and surfactant are considered, the protection scope of the lysate does not relate to the reagent such as trifluoroethanol, and the antibody enrichment is needed, and the difference from the established methodology of the research is large; from the flow, the experiment is complicated, and the steps of combining an antibody with a magnetic bead, enriching target protein, washing, resuspension and the like are involved, so that materials such as a ultrafilter tube and the like and materials such as an antibody and a target plate are also needed when the magnetic bead bond of the antibody is prepared. The nyquist diagnosis investment company patent is mainly based on MALDI-TOF technology quantification, the quantification adopts a nonlinear fitting mode according to the characteristics of the mass spectrum, in addition, in the selection of lysate (dissociating agent), protein denaturant and surfactant are considered, and antibody enrichment is needed, and the main technical points are concentrated on online SPE separation and purification and IGF-I quantification by high-resolution mass spectrum.
The foregoing background knowledge is intended to assist those of ordinary skill in the art in understanding the prior art that is closer to the present invention and to facilitate an understanding of the inventive concepts and aspects of the present application, and it should be understood that the foregoing background art should not be used to assess the novelty of the technical aspects of the present application without explicit evidence that such matter is disclosed prior to the filing date of the present application.
Disclosure of Invention
In order to solve at least one technical problem mentioned in the background art, the invention aims to provide a method and a kit for simultaneously detecting IGF-I and IGF-II based on LC-MS/MS, wherein the method remarkably reduces the complexity of a pretreatment process, can simultaneously detect IGF-I and IGF-II, and has the advantages of high sensitivity, strong specificity, good accuracy, high precision, short detection time and high detection flux.
Provided is a method for detecting human insulin-like growth factor, comprising:
protein dissociation: adding a dissociation agent and a standard internal standard solution into a sample to be detected to carry out protein dissociation;
protein precipitation: adding a precipitant into the dissociated sample solution, and taking a supernatant for later use;
and (3) solid phase extraction and purification: loading samples to the SPE plate, and eluting sequentially;
mass spectrometry detection: loading LC-MS/MS detection to obtain the Area Ratio value of the sample to be detected;
and (3) calculating: the steps of protein dissociation, protein precipitation, solid phase extraction and purification and mass spectrum detection are repeatedly carried out by replacing a sample to be detected with a standard working solution, a standard curve is obtained, and the Area Ratio value of the sample to be detected is substituted into the standard curve to calculate the content of IGF-I and IGF-II;
wherein,,
the standard internal standard solution comprises an isotope labeling diluent of IGF-I;
the standard working fluid comprises dilutions of IGF-I and IGF-II with different concentrations.
The invention also provides a human insulin-like growth factor detection kit which can quantitatively detect IGF-I and IGF-II simultaneously; the kit comprises:
a dissociating agent;
and (3) a precipitant:
standard working solution;
standard internal standard fluids, including isotopically labeled dilutions of IGF-I;
a quality control product working solution;
wherein, the standard working solution and the quality control working solution comprise diluted solutions with different concentrations of IGF-I and IGF-II, and the concentrations of IGF-I and IGF-II are different.
In some preferred embodiments, the standard working fluid comprises:
IGF-I solution at a concentration of 8, 24, 80, 200, 600, 1200ng/mL; and
IGF-II solution at a concentration of 12, 36, 120, 300, 900, 1800 ng/mL.
In some preferred embodiments, the quality control product working fluid comprises:
IGF-I solution at a concentration of 600, 200, 50 ng/mL; and
IGF-II solution at concentrations of 900, 300, 75 ng/mL.
The invention also provides application of the kit in simultaneous detection of serum or plasma IGF-I and IGF-II.
The beneficial effects of this application are:
the prior art is mainly based on MALDI-TOF technology, has high detection cost and complex pretreatment steps, and the inventor provides a method and a kit based on LC-MS/MS technology and capable of simultaneously detecting IGF-I and IGF-II in serum or plasma in consideration of enriching IGF-I detection technology and synchronously detecting IGF-I and IGF-II, wherein the pretreatment process is simple and only comprises three treatment processes: the method has the advantages that the dissociation of the analyte and the binding protein, the protein precipitation and the solid phase extraction purification can be carried out after the pretreatment is finished, the quantitative detection result can be obtained, the complexity of the pretreatment process is obviously reduced, the IGF-I and IGF-II are detected simultaneously based on the LC-MS/MS technology, the method has high sensitivity, strong specificity, good accuracy, high precision, short detection time and high detection flux, and the detection result can assist a clinician in diagnosing diseases related to abnormal IGF-I and IGF-II content in adults and/or minors.
Drawings
To make the above and/or other objects, features, advantages and examples of the present invention more comprehensible, the accompanying drawings which are needed in the detailed description of the present invention are simply illustrative of the present invention and other drawings can be obtained without inventive effort for those skilled in the art.
FIG. 1 is a flow chart of a method for simultaneous detection of IGF-I and IGF-II;
FIG. 2 is an IGF-I standard curve;
FIG. 3 is IGF-II standard curve;
FIG. 4 is a chromatogram of an IGF-I internal standard isotope;
FIG. 5 is an IGF-I chromatogram;
FIG. 6 is an IGF-II chromatogram.
Detailed Description
Suitable substitutions and/or modifications of the process parameters will be apparent to those skilled in the art from the disclosure herein, however, it is to be expressly pointed out that all such substitutions and/or modifications are intended to be encompassed by the present invention. While the products and methods of preparation of the present invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the products and methods of preparation described herein without departing from the spirit and scope of the invention.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The present invention uses the methods and materials described herein; other suitable methods and materials known in the art may be used. The materials, methods, and examples described herein are illustrative only and not intended to be limiting. All publications, patent applications, patents, provisional applications, database entries, and other references mentioned herein, and the like, are incorporated herein by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
Unless specifically stated otherwise, the materials, methods, and examples described herein are illustrative only and not intended to be limiting. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.
Unless specifically indicated, the weight ratios, percentages, and the like described herein are by volume weight ratios and volume percentages.
In order to facilitate an understanding of the embodiments of the present invention, abbreviations and key terms that may be involved in the embodiments of the present invention are first explained or defined.
LC-MS/MS: liquid chromatography-tandem mass spectrometry;
IGF-I: human insulin-like growth factor-I;
IGF-II: human insulin-like growth factor-II;
GH: growth hormone;
GHD: growth hormone deficiency;
IGFBP-3: human insulin-like growth factor binding protein 3;
calibration material: the method is used for calibrating detection items during quantitative detection;
MALDI-TOF: time-of-flight mass spectrometry;
TFE: tetrafluoroethylene;
SDS: sodium dodecyl sulfate;
CHAPS:3- [3- (cholestamidopropyl) dimethylamino ] propane sulfonic acid inner salt;
BSA: bovine serum albumin;
HQC: high-concentration quality control product working solution;
MQC: medium-concentration quality control product working solution;
LQC: low-concentration quality control product working solution;
area Ratio: area ratio.
The present invention is described in detail below.
A method for detecting human insulin-like growth factor, comprising:
protein dissociation: adding a dissociation agent and a standard internal standard solution into a sample to be detected to carry out protein dissociation;
protein precipitation: adding a precipitant into the dissociated sample solution, and taking a supernatant for later use;
and (3) solid phase extraction and purification: loading samples to the SPE plate, and eluting sequentially;
mass spectrometry detection: loading LC-MS/MS detection to obtain the Area Ratio value of the sample to be detected;
and (3) calculating: the steps of protein dissociation, protein precipitation, solid phase extraction and purification and mass spectrum detection are repeatedly carried out by replacing a sample to be detected with a standard working solution, a standard curve is obtained, and the Area Ratio value of the sample to be detected is substituted into the standard curve to calculate the content of IGF-I and IGF-II;
wherein,,
the standard internal standard solution comprises an isotope labeling diluent of IGF-I;
the standard working fluid comprises dilutions of IGF-I and IGF-II with different concentrations.
In some preferred embodiments, the protein dissociation specifically comprises: 100 mu L of sample is taken in a centrifuge tube with the volume of 1.5mL by a pipette, then a dissociating agent and an internal standard solution are added, and the sample is incubated at 37 ℃ and 500-2500 rpm.
In some preferred embodiments, the dissociating agent is at least one of TFE, SDS, or CHAPS.
In a partially preferred embodiment, the TFE is present in a volume percentage of 20 to 80%.
In a partially preferred embodiment, the volume percent of SDS is 0.2 to 0.8%.
In a partially preferred embodiment, the CHAPS is present in an amount of 0.1 to 1.0% by volume.
In some preferred embodiments, the precipitation specifically comprises: taking 50-500 mu L of precipitant by using a pipette, centrifuging for 10-40 min, taking supernatant, adding 1mL of 5% ammonia water, and uniformly mixing for later use.
In some preferred embodiments, the precipitating agent is at least one of acetonitrile, methanol, ethanol, or acetonitrile.
In a part of the preferred embodiments, the volume ratio of acetic acid and acetonitrile in the acetonitrile acetate is 5:95.
In some preferred embodiments, the volume percentages of methanol, ethanol, acetonitrile are all 100%.
In some preferred embodiments, the SPE plates are also equilibrated prior to rinsing, specifically, 500 μl of 5% ammonia is removed to the activated SPE plates and plate equilibration is performed using a biological sample pretreatment instrument.
In some preferred embodiments, the SPE plate is activated prior to equilibration, specifically, 500 μl methanol is removed into the SPE plate well and plate activation is performed using a biological sample pretreatment instrument.
In some preferred embodiments, the sample solution after the protein precipitation step is transferred to an SPE plate after the activation equilibration, and sample loading is performed using a biological sample pretreatment instrument.
In some preferred embodiments, the rinsing specifically comprises:
leaching 1: transferring 300 mu L of 5% ammonia water into the SPE plate holes, and leaching for one time by using a biological sample pretreatment instrument;
leaching 2: and transferring 300 mu L of acetic acid methanol aqueous solution into the SPE plate holes, and performing secondary leaching by using a biological sample pretreatment instrument.
In some preferred embodiments, the eluting specifically comprises:
elution 1: transferring 50 mu L of acetonitrile formate solution (0.2% formic acid and 80% acetonitrile) into a 96-well plate, eluting by using a biological sample pretreatment instrument, and repeating for 2 times;
elution 2: move and get 50 mu LddH 2 And (3) eluting in the O-96 well plate by using a biological sample pretreatment instrument, and transferring the eluent to a sample injection bottle or the 96 well plate.
In some preferred embodiments, the standard internal standard solution is at a concentration of 10 μg/mL.
In some preferred embodiments, the standard working fluid comprises:
IGF-I solution at a concentration of 8, 24, 80, 200, 600, 1200ng/mL; and
IGF-II solution at a concentration of 12, 36, 120, 300, 900, 1800 ng/mL.
The liquid chromatography-tandem mass spectrometry (liquid chromatography-tandem mass spectrometry, LC-MS/MS) technology is widely used for quantitative detection of specific protein markers due to its advantages of high sensitivity and good specificity, but unfortunately, there is no commercialized and mature detection procedure for detecting IGF-I and IGF-II in blood/plasma, and it is not possible to achieve the detection requirements of high accuracy and high precision in the process of evaluating the aforementioned factors. Based on the method, the invention provides a method for simultaneously detecting IGF-I and IGF-II based on an LC-MS/MS technology, the pretreatment flow only comprises dissociation by a dissociation agent, precipitation by a precipitator and solid-phase extraction by an SPE96 pore plate, and then mass spectrometry detection can be carried out.
The invention also provides a human insulin-like growth factor detection kit,
the kit can quantitatively detect IGF-I and IGF-II simultaneously;
the kit comprises:
a dissociating agent;
and (3) a precipitant:
standard working solution;
standard internal standard fluids, including isotopically labeled dilutions of IGF-I;
a quality control product working solution;
wherein, the standard working solution and the quality control working solution comprise diluted solutions with different concentrations of IGF-I and IGF-II, and the concentrations of IGF-I and IGF-II are different.
In some preferred embodiments, the dissociating agent is at least one of TFE, SDS, or CHAPS.
In some preferred embodiments, the precipitating agent is at least one of acetonitrile, methanol, or ethanol acetate.
In some preferred embodiments, the standard working fluid comprises:
IGF-I solution at a concentration of 8, 24, 80, 200, 600, 1200ng/mL; and
IGF-II solution at a concentration of 12, 36, 120, 300, 900, 1800 ng/mL.
In some preferred embodiments, the standard internal standard solution is at a concentration of 10 μg/mL.
In some preferred embodiments, the quality control product working fluid comprises:
IGF-I solution at a concentration of 600, 200, 50 ng/mL; and
IGF-II solution at concentrations of 900, 300, 75 ng/mL.
The kit provided by the invention obtains pure peptide fragments by using a dissociating agent and a precipitating agent, is free from the interference of other proteins such as IGFBP-3 and the like, is used for quantitative detection of human insulin-like growth factor-I and human insulin-like growth factor-II by combining an LC-MS/MS technology, wherein the single application of an isotope labeling diluent of IGF-I as a standard internal standard liquid saves detection time and detection cost, has high sensitivity, strong specificity, good accuracy, high precision, short detection time and high detection flux, and can be used for quantitative detection of IGF-I and IGF-II content in adults and/or minors.
The invention also provides application of the kit in simultaneous detection of serum or plasma IGF-I and IGF-II.
Example 1:
there is provided a kit for simultaneous detection of IGF-I and IGF-II based on an LC-MS/MS method, comprising:
a dissociating agent;
and (3) a precipitant:
standard working solution;
standard internal standard fluids, including isotopically labeled dilutions of IGF-I;
a quality control product working solution;
wherein, the standard working solution and the quality control working solution comprise diluted solutions with different concentrations of IGF-I and IGF-II, and the concentrations of IGF-I and IGF-II are different.
The dissociating agent is 0.5% SDS.
The precipitant was acetonitrile acetate (volume ratio 5:95).
The standard working solution is prepared by the following steps:
accurately weighing IGF-I and IGF-II standard substances, respectively dissolving with 0.1% BSA solution to prepare 200 mug/mL standard stock solution, and respectively diluting the stock solutions into 6 standard substance working solutions with different concentrations, wherein the specific working solutions are shown in Table 1.
TABLE 1 working fluid for Standard substance
ng/mL | STD1 | STD2 | STD3 | STD4 | STD5 | STD6 |
IGF-I | 8 | 24 | 80 | 200 | 600 | 1200 |
IGF-II | 12 | 36 | 120 | 300 | 900 | 1800 |
The standard internal standard solution is prepared by the following steps:
accurately weighing IGF-I-N15 isotope internal standard substance, and preparing 10 mug/mL working solution by using 0.1% BSA solution.
The quality control product working solution is prepared by the following steps:
accurately weighing IGF-I and IGF-II standard substances, respectively dissolving with 0.1% BSA solution to prepare 200 mug/mL standard storage liquid, and respectively diluting the standard storage liquid with three concentration gradients of high, medium and low to obtain quality control product working liquids, wherein the working liquids are shown in Table 2.
Table 2, quality control product working solution
ng/mL | HQC | MQC | LQC |
IGF-I | 600 | 200 | 50 |
IGF-II | 900 | 300 | 75 |
Example 2:
a method for simultaneously detecting IGF-I and IGF-II in a sample is provided, and the flow chart of the detection method is shown in FIG. 1.
The sample pretreatment flow comprises dissociation, precipitation and solid phase extraction.
Dissociation: 100 μl of the sample was removed by pipetting into a 1.5mL centrifuge tube, then adding the dissociating agent 40% tfe and internal standard solution and incubating at 37 ℃ at 1500 rpm.
Precipitation: taking 100 mu L of precipitator acetonitrile by using a pipette, centrifuging for 30min, taking the supernatant, adding 1mL of 5% ammonia water, and uniformly mixing for later use.
Solid phase extraction:
SPE plate activation: remove 500 μl methanol into SPE plate wells, perform plate activation using biological sample pretreatment instrument:
SPE plate balancing: transferring 500 mu L of 5% ammonia water into an SPE pore plate, and balancing the plate by using a biological sample pretreatment instrument;
loading: the sample solution after the precipitation step is moved to an SPE plate after the activation balance, and a biological sample pretreatment instrument is used for sample loading;
leaching 1: transferring 300 mu L of 5% ammonia water into the SPE plate holes, and leaching for one time by using a biological sample pretreatment instrument;
leaching 2: transferring 300 mu L of acetic acid methanol aqueous solution into SPE plate holes, and performing secondary leaching by using a biological sample pretreatment instrument;
elution 1: transferring 50 mu L of acetonitrile acetate solution (0.2% formic acid, 80% acetonitrile and the balance water) into a 96-well plate, eluting by using a biological sample pretreatment instrument, and repeating for 2 times;
elution 2: move and get 50 mu LddH 2 And (3) eluting in the O-96 well plate by using a biological sample pretreatment instrument, and transferring the eluent to a sample injection bottle or the 96 well plate.
The liquid chromatography parameters are as follows.
Sample injection amount: 10-20 mu L;
mobile phase information: fluidity a:0.1% formic acid in water, mobile phase B:0.1% acetonitrile formate solution.
The elution procedure is shown in table 3.
TABLE 3 elution procedure
Time(min) | Flow(mL/min) | B.Conc(%) |
1.0 | 0.3 | 5 |
3.0 | 0.3 | 45 |
4.5 | 0.3 | 50 |
4.6 | 0.3 | 95 |
5.6 | 0.3 | 95 |
5.7 | 0.3 | 5 |
7.0 | 0.3 | 5 |
In electrospray ionization mode (ESI), positive ion scanning mass spectrometry parameters were performed using the MRM multiple reaction monitoring mode as shown in table 4.
Table 4, positive ion scanning mass spectrometry parameters
Parameter name | Numerical value |
Air curtain gas (CUR) | 30 |
Collision gas (CAD) | 9 |
Spray voltage (IS) | 5500 |
Ionization Temperature (TEM) | 550 |
Ion source GaS1 (GS 1) | 55 |
Ion source GaS2 (GS 2) | 55 |
Injection voltage (EP) | 10 |
The mass spectrum test compound parameters are shown in table 5.
Table 5, mass spectrum detection parameters
Compounds of formula (I) | Q1 | Q3 | De-cluster voltage (DP) | Collision voltage (CE) |
IGF-I | 957 | 1175.61 | 80 | 45 |
IGF-II | 1068 | 1065.4 | 80 | 46 |
IGF-I-IS | 968.5 | 1189.7 | 100 | 45 |
Example 3:
on the basis of the previous examples, the detection of IGF-I and IGF-II in the samples is continued, the mixed standard working solution shown in the table 1 is used for replacing the samples, the pretreatment flow is carried out under the same experimental conditions, the IGF-I concentration is 8-1200 ng/mL, the IGF-II concentration is 12-1800ng/mL, the detection is carried out according to the mass spectrometry conditions of the previous examples from low to high after the sample injection, the quantitative peak area-concentration is plotted to obtain a standard curve, and the result shows that the linear range and the quantitative limit of IGF-I and IGF-II are as follows:
linear range: IGF-I: 8-1200 ng/mL; IGF-II: 12-1800 ng/mL;
quantitative limit: IGF-I:8ng/mL; IGF-II:12ng/mL;
linear coefficient: IGF-I: r= 0.99963; IGF-II: r= 0.99889;
the standard curves are shown in fig. 2 and 3, respectively.
The chromatograms of IGF-I and its internal standard isotopes IGF-I-IS and IGF-II are shown in figures 4-6, the retention time of IGF-I IS 3.72min, the retention time of IGF-II IS 3.66min, and according to figures 4-6, the detection of two compounds of IGF-I and IGF-II has high accuracy, small interference and strong specificity.
The 6 repeated test results are shown in Table 6.
TABLE 6 repeated test results
Example 4:
for the dissociation agents in the foregoing examples, 40% TFE, 0.8% SDS and 0.6% CHAPS were prepared, and these three agents were used as dissociation agents, and were treated according to the pretreatment procedure, information was collected by mass spectrometry, and the Area Ratio of IGF1 and IGF2 was calculated, respectively, and from the results, SDS performance response was the best, TFE was the worst, and all 3 agents were used as dissociation agents, and specific data are shown in table 7.
TABLE 7 Area Ratio values and precision Using different dissociating agents
For the precipitants in the foregoing examples, acetonitrile acetate (volume ratio 5:95), acetonitrile, methanol and acetone reagents were prepared and used as precipitants, respectively, pretreatment of the samples was performed according to the sample pretreatment flow, collection of mass spectra, screening of the precipitants was performed by adopting a calculation recovery method, and the results showed that acetonitrile acetate, acetonitrile and methanol could be used as precipitants, acetone could not be used as precipitants, and specific data are shown in table 8.
TABLE 8 recovery rates with different precipitants
Example 5:
standard working solutions of IGF-I and IGF-II were prepared to have 3 concentrations of high, medium and low as shown in table 9, and recovery experiments and precision verification were performed, and recovery rates and precision were measured according to the methods of the foregoing examples, as shown in tables 10 and 11, respectively.
TABLE 9 concentration by adding standard
Watch 10, precision
TABLE 11 recovery rate
By integrating the verification experiments, the quantitative limit, the linearity, the recovery rate, the precision and other technical indexes of the scheme meet the requirements, the method can simultaneously detect the IGF-I and IGF-II contents in the blood plasma/serum, the repeatability is good, the labeling recovery rate is high, and the accuracy of the detection result is improved. Meanwhile, the substrate interference can be greatly eliminated by adopting the isotope internal standard method for quantification, and the method is not influenced by the conditions of pretreatment process, sample loading volume, flow and the like, so that accurate quantification can be achieved.
The conventional technology in the above embodiments is known to those skilled in the art, and thus is not described in detail herein.
The specific embodiments described herein are offered by way of example only to illustrate the spirit of the invention. Various modifications or additions to the described embodiments may be made by those skilled in the art to which the invention pertains or may be substituted in a similar manner without departing from the spirit of the invention or beyond the scope of the appended claims.
While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the device or method illustrated may be made without departing from the spirit of the disclosure. In addition, the various features and methods described above may be used independently of one another, or may be combined in various ways. All possible combinations and subcombinations are intended to fall within the scope of this disclosure. Many of the embodiments described above include similar components, and thus, these similar components are interchangeable in different embodiments. While the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. Therefore, the present invention is not intended to be limited by the specific disclosure of the preferred embodiments herein.
The invention is a well-known technique.
Claims (10)
1. A method for detecting human insulin-like growth factor, comprising:
protein dissociation: adding a dissociation agent and a standard internal standard solution into a sample to be detected to carry out protein dissociation;
protein precipitation: adding a precipitant into the dissociated sample solution, and taking a supernatant for later use;
and (3) solid phase extraction and purification: loading samples to the SPE plate, and eluting sequentially;
mass spectrometry detection: loading LC-MS/MS detection to obtain the Area Ratio value of the sample to be detected;
and (3) calculating: the steps of protein dissociation, protein precipitation, solid phase extraction and purification and mass spectrum detection are repeatedly carried out by replacing a sample to be detected with a standard working solution, a standard curve is obtained, and the Area Ratio value of the sample to be detected is substituted into the standard curve to calculate the content of IGF-I and IGF-II;
wherein,,
the standard internal standard solution comprises an isotope labeling diluent of IGF-I;
the standard working fluid comprises serial dilutions of IGF-I and IGF-II, and the concentrations of IGF-I and IGF-II are different.
2. The method according to claim 1, characterized in that: the dissociating agent is at least one of TFE, SDS, or CHAPS.
3. The method according to claim 1, characterized in that: the precipitant is at least one of acetonitrile, methanol, ethanol or acetonitrile.
4. A method according to any one of claims 1 to 3, characterized in that: the standard working solution comprises the following components:
IGF-I solution at a concentration of 8, 24, 80, 200, 600, 1200ng/mL; and
IGF-II solution at a concentration of 12, 36, 120, 300, 900, 1800 ng/mL.
5. A human insulin-like growth factor detection kit, characterized in that:
the kit can quantitatively detect IGF-I and IGF-II simultaneously;
the kit comprises:
a dissociating agent;
and (3) a precipitant:
standard working solution;
standard internal standard fluids, including isotopically labeled dilutions of IGF-I;
a quality control product working solution;
wherein, the standard working solution and the quality control working solution comprise diluted solutions with different concentrations of IGF-I and IGF-II, and the concentrations of IGF-I and IGF-II are different.
6. The kit of claim 5, wherein: the dissociating agent is at least one of TFE, SDS, or CHAPS.
7. The kit of claim 5, wherein: the precipitant is at least one of acetonitrile, methanol, ethanol or acetonitrile.
8. The kit according to any one of claims 5 to 7, wherein: the standard working solution comprises the following components:
IGF-I solution at a concentration of 8, 24, 80, 200, 600, 1200ng/mL; and
IGF-II solution at a concentration of 12, 36, 120, 300, 900, 1800 ng/mL.
9. The kit according to any one of claims 5 to 7, wherein: the quality control product working solution comprises:
IGF-I solution at a concentration of 600, 200, 50 ng/mL; and
IGF-II solution at concentrations of 900, 300, 75 ng/mL.
10. Use of a kit according to any one of claims 5 to 9 for simultaneous detection of serum or plasma IGF-I and IGF-II.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310378354.9A CN116087386A (en) | 2023-04-11 | 2023-04-11 | Human insulin-like growth factor detection method and kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310378354.9A CN116087386A (en) | 2023-04-11 | 2023-04-11 | Human insulin-like growth factor detection method and kit |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116087386A true CN116087386A (en) | 2023-05-09 |
Family
ID=86212427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310378354.9A Pending CN116087386A (en) | 2023-04-11 | 2023-04-11 | Human insulin-like growth factor detection method and kit |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116087386A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117783389A (en) * | 2023-12-28 | 2024-03-29 | 广州金域医学检验中心有限公司 | Preparation method of IGF-1 and its variant quality control product |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0495625A2 (en) * | 1991-01-17 | 1992-07-22 | Genentech, Inc. | Assay for free IGF-I, IGF-II, and GH levels in body fluids |
WO2006090146A1 (en) * | 2005-02-23 | 2006-08-31 | Eden Research Plc | Assay |
CN105067698A (en) * | 2009-11-05 | 2015-11-18 | 奎斯特诊断投资公司 | Quantitation of insulin-like growth factor-i and insulin-like growth factor-ii with high-resolution mass spectrometry |
CN114112599A (en) * | 2021-12-10 | 2022-03-01 | 泰州泽成生物技术有限公司 | Insulin-like growth factor-I dissociation liquid |
CN114910549A (en) * | 2022-01-19 | 2022-08-16 | 融智生物科技(青岛)有限公司 | MALDI-TOF MS-based quantitative detection kit and detection method for insulin-like growth factor I |
-
2023
- 2023-04-11 CN CN202310378354.9A patent/CN116087386A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0495625A2 (en) * | 1991-01-17 | 1992-07-22 | Genentech, Inc. | Assay for free IGF-I, IGF-II, and GH levels in body fluids |
WO2006090146A1 (en) * | 2005-02-23 | 2006-08-31 | Eden Research Plc | Assay |
CN105067698A (en) * | 2009-11-05 | 2015-11-18 | 奎斯特诊断投资公司 | Quantitation of insulin-like growth factor-i and insulin-like growth factor-ii with high-resolution mass spectrometry |
CN114112599A (en) * | 2021-12-10 | 2022-03-01 | 泰州泽成生物技术有限公司 | Insulin-like growth factor-I dissociation liquid |
CN114910549A (en) * | 2022-01-19 | 2022-08-16 | 融智生物科技(青岛)有限公司 | MALDI-TOF MS-based quantitative detection kit and detection method for insulin-like growth factor I |
Non-Patent Citations (4)
Title |
---|
"临床LC-MS/MS结合固相萃取法用于人血清中胰岛素样生长因子1(IGF-1)的测定", 《岛津 EXCELLENCE IN SCIENCE》, pages 1 * |
GIULIA REMAGGI等: "Development and single laboratory validation of a targeted liquid chromatography-triple quadrupole mass spectrometry-based method for the determination of insulin like growth factor-1 in different types of milk samples", 《FOOD CHEMISTRY: X》 * |
MARK S. PRATT等: "An antibody-free LC-MS/MS method for the quantification of intact insulin-like growth factors 1 and 2 in human plasma", 《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》 * |
林美卿: "IGF-1对肾小管上皮细胞转分化作用机制的影响", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, no. 12 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117783389A (en) * | 2023-12-28 | 2024-03-29 | 广州金域医学检验中心有限公司 | Preparation method of IGF-1 and its variant quality control product |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007275638B2 (en) | Method of detecting and/ or measuring hepcidin in a sample | |
Mischak et al. | High‐resolution proteome/peptidome analysis of peptides and low‐molecular‐weight proteins in urine | |
CN113063871B (en) | Metabolic small molecule detection method and detection system | |
CN108291916B (en) | Detection of amyloid beta by mass spectrometry | |
CN116087386A (en) | Human insulin-like growth factor detection method and kit | |
CN111879876A (en) | Rapid and sensitive analysis method for 25 hydroxyvitamin D based on immune mass spectrometry technology | |
CN115876933A (en) | Method for detecting steroid hormone in serum | |
CN112485418B (en) | Release agent for detecting vitamin B12 content of human body and application thereof | |
CN114112594B (en) | Insulin-like growth factor-1 pretreatment reagent | |
CN116499822A (en) | IGF-I sample pretreatment method and kit based on triple quadrupole mass spectrometer | |
CN114910549A (en) | MALDI-TOF MS-based quantitative detection kit and detection method for insulin-like growth factor I | |
CN114624362A (en) | Kit for detecting advanced glycosylation end products in serum and application thereof | |
US20220276270A1 (en) | Pretreatment method of an automatic analyzer | |
JP7438224B2 (en) | Fast sample workflow for HbA1c measurement based on LC-MS | |
Zhang et al. | Expression, purification and identification of isotope-labeled recombinant cystatin C protein in Escheichia coli intended for absolute quantification using isotope dilution mass spectrometry | |
CN115684432B (en) | Method and kit for detecting calprotectin content in blood | |
CN117269402B (en) | Liquid phase mass spectrum combination method for quantitatively detecting norcinnabar in human cerebrospinal fluid | |
JP2022517414A (en) | Automated sample workflow for LC-MS-based HbA1c measurements at the intact protein level | |
CN117250301B (en) | Liquid phase mass spectrum combined method for quantitatively detecting norcinnabar in human plasma | |
US20230251277A1 (en) | Method for determining the level of vitamin d and metabolites thereof | |
JP2024032761A (en) | Use of lc-ms/ms to quantitate protein biomarkers | |
CN117630263A (en) | Method for detecting various free amino acids in plasma based on liquid chromatography-tandem mass spectrometry | |
CN116399982A (en) | Biological analysis method for detecting concentration of cefaclor in blood plasma | |
CN116609451A (en) | Quality control product for quality control in thyroid nodule mass spectrometry detection process | |
CN117471007A (en) | Plasma beta-amyloid detection method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |